A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

##STR00001##

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) ##STR00001##
in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2, R.sup.3, R.sup.4, R.sup.5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) ##STR00001##
in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2, R.sup.3, R.sup.4, R.sup.5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

Pyridazinedione-based heterobicyclic covalent linkers useful for formation of protein-drug conjugates, protein-protein conjugates, or the like, preparation methods thereof, and applications of the linkers in formation of various protein conjugates are disclosed. The present disclosure provides a new class of linkers to overcome the limitations of the existing pyridazinedione-based linkers. These linkers can be synthesized from commercially available starting materials in 1-3 steps and are highly reactive toward the thiols derived from the reduction of disulfide bridges in proteins.

Pyridazinedione-based heterobicyclic covalent linkers useful for formation of protein-drug conjugates, protein-protein conjugates, or the like, preparation methods thereof, and applications of the linkers in formation of various protein conjugates are disclosed. The present disclosure provides a new class of linkers to overcome the limitations of the existing pyridazinedione-based linkers. These linkers can be synthesized from commercially available starting materials in 1-3 steps and are highly reactive toward the thiols derived from the reduction of disulfide bridges in proteins.

Disclosed is a process for preparing dihydro-2H-pyran derivatives of formula I: ##STR00001## wherein R.sup.1 and R.sup.2 are defined herein. The process of the invention provides the compound of formula I in concise cascade reactions and in one pot. The compound of formulae I prepared by the process of the invention and its further transformed derivatives are useful for making pharmaceutical composition for the treatment of proliferative diseases.

Disclosed is a process for preparing dihydro-2H-pyran derivatives of formula I: ##STR00001## wherein R.sup.1 and R.sup.2 are defined herein. The process of the invention provides the compound of formula I in concise cascade reactions and in one pot. The compound of formulae I prepared by the process of the invention and its further transformed derivatives are useful for making pharmaceutical composition for the treatment of proliferative diseases.